rational combinations of targeted agents

[Guest guest]

Novel therapeutic agents for B-cell lymphoma: developing rational

combinations

Fairly technical but a useful review of the landscape, providing summary

discussion of 1) the class of drug, the 2) mechanism of activity, 3) its use

so far in lymphoma, and 4) toxicities.

A few snips:

" Historically, the predominant approach to cancer therapy has been to

develop agents that specifically inhibit the growth of the malignant cell.

This selective inhibition has largely relied on the fact that the malignant

cells proliferate faster than normal cells or express certain proteins more

abundantly than nonmalignant cells. More recent data have shown that the

tumor microenvironment may also be a valid therapeutic target because

surrounding normal cells may provide support for the malignant cell. "

..

" The exact mechanism of immunomodulatory (IMiD) activity is unclear and may

be different for different diseases. Much of what is known comes from data

in myeloma cell lines. IMiDs have been shown to be antiproliferative, and in

greater doses lenalidomide and pomalidomide can cause off-target

myelosuppression. The direct antiproliferative effects may be caused by

down-regulation of nuclear factor êB (NFêB)10 and direct stimulation of the

intrinsic apoptotic pathway. "

Full text: http://bit.ly/i7c7qs

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm